Dr. Kenneth Rosenthal is the U.S. medical monitor for an ongoing FDA clinical trial of the Artisan Aphakia IOL (Ophtec) in children. In this discussion from ASCRS 2015, Dr. Rosenthal discusses the history of this unique IOL design and its advantages in a pediatric population. Because the IOL can be unclipped from the iris with a simple, relatively atraumatic motion and exchanged with a new IOL of appropriate power, it offers a less traumatic IOL exchange procedure as the child grows. Also known as the Iris Claw IOL, it is designed for primary or secondary implantation when placement of a posterior chamber IOL in the posterior chamber is not indicated and when an anterior chamber angle fixated intraocular lens is determined to not be in the patient’s best interest. Dr. Rosenthal says the Aphakia IOL is increasingly being used as the back-up lens of choice by many cataract surgeons outside the United States. Approximately 450,000 Aphakia IOLs have been implanted worldwide.